Navigation Links
WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
Date:8/22/2008

SHANGHAI, China, Aug. 22 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has promoted Dr. Rujian Ma to Vice President of Synthetic Chemistry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Dr. Ma will report directly to Dr. Shuhui Chen, Chief Scientific Officer of WuXi PharmaTech.

"I am very delighted to promote Dr. Ma to this new leadership position. Dr. Ma's depth of synthetic chemistry experience and his commitment and coaching capabilities of our young scientists undoubtedly will further accelerate the development of our core synthetic chemistry division. His new assignment will also help us continually improve our service quality and productivity and to serve our customers better." commented Dr. Shuhui Chen, Chief Scientific Officer of WuXi PharmaTech.

Dr. Ma received his Ph.D. in Organic Chemistry from the University of Tokushima, Japan and joined in WuXi in March 2001.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
2. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
3. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
4. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
5. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
6. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
7. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
8. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
9. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
10. WuXi PharmaTech Announces First Quarter 2008 Results
11. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2020)... ... June 30, 2020 , ... Flagship ... of a new clinical diagnostics immuno-oncology service, TissueInsight . TissueInsight provides ... “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists in ...
(Date:6/28/2020)... ... June 25, 2020 , ... With the ... vaccine or drug treatment. In an effort to better understand the cellular responses ... world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 approved and ...
(Date:6/28/2020)... ... June 26, 2020 , ... The ... today announced its strong opposition to the recently introduced bicameral Facial Recognition ... ban on most federal use of nearly all biometric and related image analytics ...
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis Corporation, the premier ... that Derek Fournier has been appointed CEO and President. Founder and former CEO, ... , “DeCurtis Corporation has been on an incredible journey for the last ...
Breaking Biology Technology:
(Date:6/5/2020)... , ... June 04, 2020 , ... Greffex, a pioneering ... its Board of Directors. , “Neil understands the need for a global perspective to ... and CEO of Greffex. Mr. Bush will serve as an independent, director of the ...
(Date:5/28/2020)... ... May 27, 2020 , ... ... Advisor™ , a solution that uniquely combines lab testing insights and hc1’s exclusive ... support the ongoing health and safety of employees returning to the workplace. , ...
(Date:5/25/2020)... ... May 22, 2020 , ... Oxford Nanopore Technologies is ... of SARS-CoV-2, the virus that causes COVID-19. , The LamPORE assay is ... smaller sample numbers, to very large numbers of samples. Hardware and reagents sit ...
Breaking Biology News(10 mins):